We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026

Rapid Flow-Through Testing Technology Expanded for HIV Diagnosis

By HospiMedica staff writers
Posted on 24 Dec 2007
A new range of rapid HIV testing products is being produced utilizing a new scientific test platform. More...


The core technology platform, which is the basis a new generation of infectious disease testing products, includes a rapid flow-through diagnostic device, assay, and multi-functional buffer.

The rapid diagnostic tests were developed by MedMira (Halifax, Canada) and are to be sold by the German company Vitest (Hennigsdorf, Germany). This is the first shipment of MedMira's private label product to a distributor in Europe. Under the private label agreement, Vitest will market and sell the new product under the Vitest brand and it will be a part of the Vitest suite of rapid testing products.

"Our rapid flow-through technology platform has an endless list of potential applications, for which our current product pipeline has barely scratched the surface,” said Hermes Chan, president and CEO of MedMira. "Our strategic goals involve the pursuit of a wide range of opportunities to diversify not only our own product portfolio, but also to make available a private label or OEM [original equipment manufacturer] capability to fill the needs of our partners. We are pleased to welcome Vitest as our first partner in this endeavor.”

MedMira is a developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics, and individuals worldwide with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal, MiraWell, MiraCare, and Multiplo brands. MedMira's rapid HIV test has achieved regulatory approvals in Canada, the United States, China, and the European Union.

The Maple Biosciences division of MedMira develops and commercializes diagnostic instruments based on two new biosensor-based technology platforms. Solutions developed by The Maple Biosciences division of MedMira enable routine laboratory tests to be performed in minutes, increasing laboratory automation, and streamlining the diagnosis of multiple conditions and diseases.


Related Links:
MedMira
Vitest

Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
HPV Test
Allplex HPV28 Detection
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.